IMUNON INC
IMNNNASDAQTrading Snapshot
- Day Range
- $0.53 โ $0.58
- 52-Week Range
- $0.50 โ $4.35
- Volume (shares)
- 49,701
- Avg Volume (shares)
- โ
- Shares Outstanding
- 6.5M
- Next Earnings
- 2027-03-29
Fundamentals Snapshot
- Annual Revenue
- โ
- Last Q Revenue
- โ
- P/E Ratio
- -0.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.53
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +91.0%
IMUNON INC
IMNNAbout IMUNON INC
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
โLatest News & Updates

Imunon, Inc. (IMNN) Q3 2026 Earnings Call Transcript
Imunon, Inc. (IMNN) Q3 2026 Earnings Call Transcript

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update
IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer

IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer
Analysis of paired patient biopsies from the randomized Phase 2 OVATION 2 study shows IMNN-001 increased CD8+/Treg, CD8+/CD4+ and CD8+/IDO+ ratios in both tumor and stroma

IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026
LAWRENCEVILLE, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a conference

IMUNON Announces Strategic Sale of ThermoDoxยฎ
Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial

IMUNON to Participate in Upcoming Investor Conferences
LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy Lindborg, Ph.D.